Cancer wars: Natural products strike back

Frontiers in Chemistry

Volumn 2, Issue MAY, 2014, Pages

  Basmadjian, Christine ^a,b   Zhao, Qian ^a,b   Bentouhami, Embarek ^c   Djehal, Amel ^a,c   Nebigil, Canan G ^a   Johnson, Roger A ^d   Serova, Maria ^b   de Gramont, Armand ^b   Faivre, Sandrine ^b,e   Raymond, Eric ^b,e   Désaubry, Laurent G ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b AAREC Filia Research   (France)

^c FERHAT ABBAS UNIVERSITY   (Algeria)

^d STONY BROOK UNIVERSITY   (United States)

^e BEAUJON HOSPITAL   (France)

Author keywords

Cancer; Drug discovery; Molecular targets; Natural products; Pharmacognosy; Privileged structures

Indexed keywords

EID: 84987621385     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00020     Document Type: Review

References (147)

1. Aicher, T. D., Buszek, K. R., Fang, F. G., Forsyth, C. J., Jung, S. H., Kishi, Y., et al. (1992). Total synthesis of halichondrin B and norhalichondrin B. J. Am. Chem. Soc. 114, 3162-3164. doi: 10.1021/ja00034a086
2. Ares, J., Durán-Peña, M. J., Hernández-Galán, R., and Collado, I. (2013). Chemical genetics strategies for identification of molecular targets. Phytochem. Rev. 12, 895-914. doi: 10.1007/s11101-013-9312-6
3. Bailly, C. (2009). Ready for a comeback of natural products in oncology. Biochem. Pharmacol. 77, 1447-1457. doi: 10.1016/j.bcp.2008.12.013
4. Balog, A., Meng, D., Kamenecka, T., Bertinato, P., Su, D.-S., Sorensen, E. J., et al. (1996). Totalsynthese von (-)-Epothilon A. Angew. Chem. 108, 2976-2978. doi: 10.1002/ange.19961082318
5. Basmadjian, C., Thuaud, F., Ribeiro, N., and Désaubry, L. (2013). Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A. Future Med. Chem. 5, 2185-2197. doi: 10.4155/fmc.13.177
6. Basu, P. (2004). Trading on traditional medicines. Nat. Biotechnol. 22, 263-265. doi: 10.1038/nbt0304-263
7. Benhadji, K. A., Serova, M., Ghoul, A., Cvitkovic, E., Le Tourneau, C., Ogbourne, S. M., et al. (2008). Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br. J. Cancer 99, 1808-1815. doi: 10.1038/sj.bjc.6604642
8. Bennouna, J., Campone, M., Delord, J. P., and Pinel, M.-C. (2005). Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin. Investig. Drugs 14, 1259-1267. doi: 10.1517/13543784.14.10.1259
9. Bennouna, J., Fumoleau, P., Armand, J.-P., Raymond, E., Campone, M., Delgado, F.-M., et al. (2003). Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann. Oncol. 14, 630-637. doi: 10.1093/annonc/mdg174
10. Bode, J. W., and Carreira, E. M. (2001). Stereoselective syntheses of epothilones A and B via directed nitrile oxide cycloaddition1. J. Am. Chem. Soc. 123, 3611-3612. doi: 10.1021/ja0155635
11. Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., et al. (1995). Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325-2333.
12. Bonfanti, M., La Valle, E., Fernandez Sousa Faro, J. M., Faircloth, G., Caretti, G., Mantovani, R., et al. (1999). Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 14, 179-186.
13. Brown, E. J., Albers, M. W., Tae Bum, S., Ichikawa, K., Keith, C. T., Lane, W. S., et al. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758. doi: 10.1038/369756a0
14. Calne, R. Y. (2003). The development of immunosuppression: the rapamycin milestone. Transplant. Proc. 35, S15-S17. doi: 10.1016/S0041-1345(03)00209-4
15. Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., et al. (1989). Rapamycin for immunosuppression in organ allografting. The Lancet 334, 227. doi: 10.1016/S0140-6736(89)90417-0
16. Chen, J., Chen, X., Bois-Choussy, M. L., and Zhu, J. (2006). Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 128, 87-89. doi: 10.1021/ja0571794
17. Cordell, G. A., and Colvard, M. D. (2012). Natural products and traditional medicine: turning on a paradigm. J. Nat. Prod. 75, 514-525. doi: 10.1021/np200803m
18. Corey, E. J., Gin, D. Y., and Kania, R. S. (1996). Enantioselective total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 118, 9202-9203. doi: 10.1021/ja962480t
19. Cuevas, C., and Francesch, A. (2009). Development of Yondelis[registered sign] (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 26, 322-337. doi: 10.1039/b808331m
20. Cuevas, C., Pérez, M., Martin, M. J., Chicharro, J. L., Fernandez-Rivas, C., Flores, M., et al. (2000). Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett. 2, 2545-2548. doi: 10.1021/ol0062502
21. Cvek, B. (2012). Nonprofit drugs as the salvation of the world's healthcare systems: the case of antabuse (disulfiram). Drug Discov. Today 17, 409-412. doi: 10.1016/j.drudis.2011.12.010
22. D'Incalci, M., and Jimeno, J. (2003). Preclinical and clinical results with the natural marine product ET-743. Expert Opin. Investig. Drugs 12, 1843-1853. doi: 10.1517/13543784.12.11.1843
23. D'Incalci, M., and Galmarini, C. M. (2010). A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9, 2157-2163. doi: 10.1158/1535-7163.mct-10-0263
24. Dancík, V., Seiler, K. P., Young, D. W., Schreiber, S. L., and Clemons, P. A. (2010). Distinct biological network properties between the targets of natural products and disease genes. J. Am. Chem. Soc. 132, 9259-9261. doi: 10.1021/ja102798t
25. Ducry, L. (2012). Challenges in the development and manufacturing of antibody-drug conjugates. Methods Mol. Biol. 899, 489-497. doi: 10.1007/978-1-61779-921-1_29
26. Ehrlich, P. (1897). Zur kenntnis der antitoxinwirkung. Fortschr. Med. 15, 41-43.
27. Endo, A., Yanagisawa, A., Abe, M., Tohma, S., Kan, T., and Fukuyama, T. (2002). Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 124, 6552-6554. doi: 10.1021/ja026216d
28. Estève, M.-A., Carré, M., Bourgarel-Rey, V., Kruczynski, A., Raspaglio, G., Ferlini, C., et al. (2006). Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol. Cancer Ther. 5, 2824-2833. doi: 10.1158/1535-7163.mct-06-0277
29. Etiévant, C., Barret, J.-M., Kruczynski, A., Perrin, D., and Hill, B. (1998). Vinflunine (20', 20'-difluoro-3', 4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest. New Drugs 16, 3-17. doi: 10.1023/A:1006022811895
30. Etiévant, C., Kruczynski, A., Barret, J.-M., Tait, A., Kavallaris, M., and Hill, B. (2001). Markedly diminished drug resistance-inducing properties of vinflunine (20', 20'-difluoro-3', 4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol. 48, 62-70. doi: 10.1007/s002800100275
31. Evans, B. E., Rittle, K. E., Bock, M. G., Dipardo, R. M., Freidinger, R. M., Whitter, W. L., et al. (1988). Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31, 2235-2246. doi: 10.1021/jm00120a002
32. Fahy, J., Duflos, A., Ribet, J.-P., Jacquesy, J.-C., Berrier, C., Jouannetaud, M.-P., et al. (1997). Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J. Am. Chem. Soc. 119, 8576-8577. doi: 10.1021/ja971864w
33. Faivre, S., and Raymond, E. (2008). Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin. Investig. Drugs 17, 1619-1621. doi: 10.1517/13543784.17.11.1619
34. Ferlini, C., Cicchillitti, L., Raspaglio, G., Bartollino, S., Cimitan, S., Bertucci, C., et al. (2009). Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 69, 6906-6914. doi: 10.1158/0008-5472
35. Findlay, J. A., and Radics, L. (1980). On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin. Can. J. Chem. 58, 579-590. doi: 10.1139/v80-090
36. Fishlock, D., and Williams, R. M. (2008). Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis. J. Org. Chem. 73, 9594-9600. doi: 10.1021/jo801159k
37. Fresno, M., Jiménez, A., and Vázquez, D. (1977). Inhibition of translation in eukaryotic systems by harringtonine. Eur. J. Biochem. 72, 323-330. doi: 10.1111/j.1432-1033.1977.tb11256.x
38. Furumai, R., Matsuyama, A., Kobashi, N., Lee, K. H., Nishiyama, M., Nakajima, H., et al. (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916-4921
39. Galsky, M. D., Dritselis, A., Kirkpatrick, P., and Oh, W. K. (2010). Cabazitaxel. Nat. Rev. Drug Discov. 9, 677-678. doi: 10.1038/nrd3254
40. Ganesan, A. (2008). The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 12, 306-317. doi: 10.1016/j.cbpa.2008.03.016
41. Gerhardt, C. (1853). Untersuchungen über die wasserfreien organischen Säuren. Justus Liebigs Ann. Chem. 87, 57-84. doi: 10.1002/jlac.18530870107
42. Gerth, K., Bedorf, N., Hofle, G., Irschik, H., and Reichenbach, H. (1996). Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. (Tokyo) 49, 560-563. doi: 10.7164/antibiotics.49.560
43. Ghose, T., Guclu, A., and Tai, J. (1975). Suppression of an AKR Lymphoma by antibody and chlorambucil. J. Natl. Cancer Inst. 55, 1353-1357. doi: 10.1093/jnci/55.6.1353
44. Ghoul, A. D., Serova, M., Astorgues-Xerri, L., Bieche, I., Bousquet, G., Varna, M., et al. (2009). Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 69, 4260-4269. doi: 10.1158/0008-5472.can-08-2837
45. Goss, R. J. M., Shankar, S., and Fayad, A. A. (2012). The generation of "unNatural" products: synthetic biology meets synthetic chemistry. Nat. Prod. Rep. 29, 870-889. doi: 10.1039/C2NP00001F
46. Grabowski, K., Baringhaus, K.-H., and Schneider, G. (2008). Scaffold diversity of natural products: inspiration for combinatorial library design. Nat. Prod. Rep. 25, 892-904. doi: 10.1039/B715668P
47. Green, A. C., and Beardmore, G. L. (1988). Home treatment of skin cancer and solar keratoses. Australas. J. Dermatol. 29, 127-130. doi: 10.1111/j.1440-0960.1988.tb00383.x
48. Groll, M., Kim, K. B., Kairies, N., Huber, R., and Crews, C. M. (2000). Crystal structure of the 20 s proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J. Am. Chem. Soc. 122, 1237-1238. doi: 10.1021/ja993588m
49. Group, C. R. C. (1976). Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin. Med. J. (Engl). 2, 263-272.
50. Gunasekera, S. P., Gunasekera, M., Longley, R. E., and Schulte, G. K. (1990). Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J. Org. Chem. 55, 4912-4915. doi: 10.1021/jo00303a029
51. Handratta, V. D., Vasaitis, T. S., Njar, V. C. O., Gediya, L. K., Kataria, R., Chopra, P., et al. (2005). Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972-2984. doi: 10.1021/jm040202w
52. Hardy, K., Buckley, S., Collins, M. J., Estalrrich, A., Brothwell, D., Copeland, L., et al. (2012). Neanderthal medics? Evidence for food, cooking, and medicinal plants entrapped in dental calculus. Naturwissenschaften 99, 617-626. doi: 10.1007/s00114-012-0942-0
53. Henkel, T., Brunne, R. M., Müller, H., and Reichel, F. (1999). Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed. Engl. 38, 643-647. doi: 10.1002/(SICI)1521-3773(19990301)38:5<643::AID-ANIE643>3.0.CO;2-G
54. Hietman, J., Movva, N. R., and Hall, M. N. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909. doi: 10.1126/science.1715094
55. Hirata, Y., and Uemura, D. (1986). Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 58, 701-710. doi: 10.1351/pac198658050701
56. Ho, R. J. Y., and Chien, J. (2014). Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. J. Pharm. Sci. 103, 71-77. doi: 10.1002/jps.23761
57. Hofheinz, R. D., Gnad-Vogt, S. U., Beyer, U., and Hochhaus, A. (2005). Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16, 691-707. doi: 10.1097/01.cad.0000167902.53039.5a
58. Höfle, G., Bedorf, N., Steinmetz, H., Schomburg, D., Gerth, K., and Reichenbach, H. (1996). Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew. Chem. Int. Ed. Engl. 35, 1567-1569. doi: 10.1002/anie.199615671
59. Horwitz, S. B. (1994). Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5(Suppl. 6), S3-S6.
60. Huang, M. T. (1975). Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 11, 511-519.
61. Imai, T., Nakata, H., Yokoshima, S., and Fukuyama, T. (2012). Synthetic studies toward ecteinascidin 743 (Trabectedin). Synthesis 44, 2743-2753. doi: 10.1055/s-0032-1316579
62. Jackson, K. L., Henderson, J. A., and Phillips, A. J. (2009). The halichondrins and E7389. Chem. Rev. 109, 3044-3079. doi: 10.1021/cr900016w
63. Jarman, M., Barrie, S. E., and Llera, J. M. (1998). The 16, 17-double bond is needed for irreversible inhibition of human cytochrome P45017a by abiraterone (17-(3-Pyridyl)androsta-5, 16-dien-3β-ol) and related steroidal inhibitors. J. Med. Chem. 41, 5375-5381. doi: 10.1021/jm981017j
64. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. (2000). Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. U.S.A. 97, 6775-6779. doi: 10.1073/pnas.97.12.6775
65. Johnson, P., Geldart, T., Fumoleau, P., Pinel, M.-C., Nguyen, L., and Judson, I. (2006). Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest. New Drugs 24, 223-231. doi: 10.1007/s10637-005-3902-0
66. Jordan, M. A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265. doi: 10.1038/nrc1317
67. Jørgensen, L., McKerrall, S. J., Kuttruff, C. A., Ungeheuer, F., Felding, J., and Baran, P. S. (2013). 14-step synthesis of (+)-ingenol from (+)-3-carene. Science 341, 878-882. doi: 10.1126/science.1241606
68. Kahan, B. D., Chang, J. Y., and Sehgal, S. N. (1991). Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 52, 185-191. doi: 10.1097/00007890-199108000-00001
69. Kantarjian, H. M., O'Brien, S., and Cortes, J. (2013). Homoharringtonine/Omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin. Lymphoma Myeloma Leuk. 13, 530-533. doi: 10.1016/j.clml.2013.03.017
70. Kawagishi, F., Toma, T., Inui, T., Yokoshima, S., and Fukuyama, T. (2013). Total synthesis of ecteinascidin 743. J. Am. Chem. Soc. 135, 13684-13687. doi: 10.1021/ja408034x
71. Kim, T. Y., Kim, D. W., Chung, J. Y., Shin, S. G., Kim, S. C., Heo, D. S., et al. (2004). Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10, 3708-3716. doi: 10.1158/1078-0432.CCR-03-0655
72. King, M. L., Chiang, C. C., Ling, H. C., Ochiai, M., Fujita, E., and Mcphail, A. T. (1985). X-Ray crystal structure of rocaglamide, a novel antileulemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J. Chem. Soc. Chem. Commun. 1982, 1150-1151. doi: 10.1039/C39820001150
73. Kino, T., Hatanaka, H., Hashimoto, M., Nishiyama, M., Goto, T., Okuhara, M., et al. (1987a). FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40, 1249-1255.
74. Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T., et al. (1987b). FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 40, 1256-1265.
75. Kirikae, T., Ojima, I., Kirikae, F., Ma, Z., Kuduk, S. D., Slater, J. C., et al. (1996). Structural requirements of taxoids for nitric oxide and tumor necrosis factor production by murine macrophages. Biochem. Biophys. Res. Commun. 227, 227-235. doi: 10.1006/bbrc.1996.1494
76. Kirschning, A., and Hahn, F. (2012). Merging chemical synthesis and biosynthesis: a new chapter in the total synthesis of natural products and natural product libraries. Angew. Chem. Int. Ed. Engl. 51, 4012-4022. doi: 10.1002/anie.201107386
77. Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497. doi: 10.1038/256495a0
78. Krysiak, J., and Breinbauer, R. (2012). Activity-based protein profiling for natural product target discovery. Top. Curr. Chem. 324, 43-84. doi: 10.1007/128_2011_289
79. Leamon, C. P., and Low, P. S. (1991). Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 88, 5572-5576. doi: 10.1073/pnas.88.13.5572
80. Lee, F. F., Borzilleri, R., Fairchild, C., Kamath, A., Smykla, R., Kramer, R., et al. (2008). Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother. Pharmacol. 63, 157-166. doi: 10.1007/s00280-008-0724-8
81. Lee, F. Y. F., Vite, G., Borzilleri, R. M., Arico, M. A., Clark, J. L., Fager, K. L., et al. (2000). Preclinical pharmacology of the epothilone B analog BMS-247550-an epothilone analog possessing potent activity against paclitaxel sensitive and resistant human tumors. Clin. Cancer Res. 6:4580s.
82. Lee, M.-L., and Schneider, G. (2001). Scaffold architecture and pharmacophoric properties of natural products and trade drugs:? application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 3, 284-289. doi: 10.1021/cc000097l
83. Lindel, T., Jensen, P. R., Fenical, W., Long, B. H., Casazza, A. M., Carboni, J., et al. (1997). Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J. Am. Chem. Soc. 119, 8744-8745. doi: 10.1021/ja9717828
84. Loc, T. B., Mathé, G., and Bernard, J. (1958). Effet sur la leucémie 1210 de la souris d'une combinaison par diazotation d'A-méthopterine ct de γ-globulins de hamsters porteurs de cette leucémic par hétérogreffe. C. R. Acad. Sci. Paris 246, 1626-1628.
85. Martinez, E. J., Owa, T., Schreiber, S. L., and Corey, E. J. (1999). Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc. Natl. Acad. Sci. U.S.A. 96, 3496-3501. doi: 10.1073/pnas.96.7.3496
86. McAlpine, J. B., Swanson, S. J., Jackson, M., and Whittern, D. N. (1991). Revised NMR assignments for rapamycin. J. Antibiot. (Tokyo) 44, 688-690. doi: 10.7164/antibiotics.44.688
87. Menchaca, R., Martinez, V., Rodriguez, A., Rodriguez, N., Flores, M., Gallego, P., et al. (2003). Synthesis of natural ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from cyanosafracin B. J. Org. Chem. 68, 8859-8866. doi: 10.1021/jo034547i
88. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., and Mantovani, R. (2000). Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. U.S.A. 97, 6780-6784. doi: 10.1073/pnas.97.12.6780
89. Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., and Davidson, B. S. (1999). Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res. 59, 653-660.
90. Mulzer, J., Mantoulidis, A., and Öhler, E. (2000). Total syntheses of epothilones B and D. J. Org. Chem. 65, 7456-7467. doi: 10.1021/jo0007480
91. Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., and Horinouchi, S. (1998). FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241, 126-133. doi: 10.1006/excr.1998.4027
92. Nicolaou, K. C., Ninkovic, S., Sarabia, F., Vourloumis, D., He, Y., Vallberg, H., et al. (1997). Total syntheses of epothilones A and B via a macrolactonization-based strategy. J. Am. Chem. Soc. 119, 7974-7991. doi: 10.1021/ja971110h
93. Nishizuka, Y. (1984). The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308, 693-698. doi: 10.1038/308693a0
94. Noble, R. L., Beer, C. T., and Cutts, J. H. (1959). Further biological activities of vincaleukoblastine-an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol. 1, 347-348. doi: 10.1016/0006-2952(59)90123-6
95. Ojima, I., Chakravarty, S., Inoue, T., Lin, S., He, L., Horwitz, S. B., et al. (1999). A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. U.S.A. 96, 4256-4261. doi: 10.1073/pnas.96.8.4256
96. Ortholand, J.-Y., and Ganesan, A. (2004). Natural products and combinatorial chemistry: back to the future. Curr. Opin. Chem. Biol. 8, 271-280. doi: 10.1016/j.cbpa.2004.04.011
97. Paudler, W. W., Kerley, G. I., and McKay, J. (1963). The alkaloids of Cephalotaxus drupacea and Cephalotaxus fortunei. J. Org. Chem. 28, 2194-2197. doi: 10.1021/jo01044a010
98. Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. (1996). DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata. Biochemistry 35, 13303-13309. doi: 10.1021/bi960306b
99. Potter, G. A., Barrie, S. E., Jarman, M., and Rowlands, M. G. (1995). Novel steroidal inhibitors of human cytochrome P45017.alpha.-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463-2471. doi: 10.1021/jm00013a022
100. Powell, R. G., Weisleder, D., and Smith, C. R. (1972). Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J. Pharm. Sci. 61, 1227-1230. doi: 10.1002/jps.2600610812
101. Powell, R. G., Weisleder, D., Smith C. R. Jr., and Rohwedder, W. K. (1970). Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 11, 815-818. doi: 10.1016/S0040-4039(01)97839-6
102. Pucheault, M. (2008). Natural products: chemical instruments to apprehend biological symphony. Org. Biomol. Chem. 6, 424-432. doi: 10.1039/b713022h
103. Qi, Y., and Ma, S. (2011). The medicinal potential of promising marine macrolides with anticancer activity. ChemMedChem 6, 399-409. doi: 10.1002/cmdc.201000534
104. Rehman, Y., and Rosenberg, J. E. (2012). Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des. Devel. Ther. 6, 13-18. doi: 10.2147/DDDT.S15850
105. Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F., et al. (1990). Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem. 55, 4512-4515. doi: 10.1021/jo00302a007
106. Ritter, S. K. (2013). 2013's notable advances. Chem. Eng. News 91, 16-19.
107. Robin, J.-P., Dhal, R., Dujardin, G., Girodier, L., Mevellec, L., and Poutot, S. (1999). The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett. 40, 2931-2934. doi: 10.1016/S0040-4039(99)00327-5
108. Roin, B. N. (2009). Unpatentable drugs and the standards of patentability. Tex. Law Rev. 87, 503-570.
109. Santagata, S., Mendillo, M. L., Tang, Y.-C., Subramanian, A., Perley, C. C., Roche, S. P., et al. (2013). Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 341, 1238303-1-1238303-10. doi: 10.1126/science.1238303
110. Sayed, M. D., Riszk, A., Hammouda, F. M., El-Missiry, M. M., Williamson, E. M., and Evans, F. J. (1980). Constituents of Egyptian Euphorbiaceae. IX. Irritant and cytotoxic ingenane esters from Euphorbia paralias L. Experientia 36, 1206-1207. doi: 10.1007/BF01976131
111. Schinzer, D., Limberg, A., Bauer, A., Böhm, O. M., and Cordes, M. (1997). Total synthesis of (-)-epothilone A. Angew. Chem. Int. Ed. Engl. 36, 523-524. doi: 10.1002/anie.199705231
112. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012). Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287. doi: 10.1038/nrc3236
113. Sehgal, S. N., Baker, H., and Vezina, C. (1975). Rapamycin (AY 22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727-732.
114. Serova, M., Ghoul, A. D., Benhadji, K. A., Faivre, S., Le Tourneau, C., Cvitkovic, E., et al. (2008). Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol. Cancer Ther. 7, 915-922. doi: 10.1158/1535-7163.mct-07-2060
115. Sigel, M. M., Wellham, L. L., Lichter, W., Dudeck, L. E., Gargus, J. L., and Lucas, A. H. (1970). "Anticellular and antitumor activity of extracts from tropical marine invertebrates, " in Food-Drugs from the Sea Proceedings 1969, ed H. W. Youngken Jr. (Washington, DC: Marine Technology Society), 281-294.
116. Siller, G., Gebauer, K., Welburn, P., Katsamas, J., and Ogbourne, S. M. (2009). PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas. J. Dermatol. 50, 16-22. doi: 10.1111/j.1440-0960.2008.00497.x
117. Su, D.-S., Meng, D., Bertinato, P., Balog, A., Sorensen, E. J., Danishefsky, S. J., et al. (1997). Total synthesis of (-)-epothilone B: an extension of the suzuki coupling method and insights into structure-activity relationships of the epothilones. Angew. Chem. Int. Ed. Engl. 36, 757-759. doi: 10.1002/anie.199707571
118. Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., and Bhattacharya, S. K. (2007). Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581. doi: 10.1056/NEJMoa066536
119. Swindells, D. C. N., White, P. S., and Findlay, J. A. (1978). The X-ray crystal structure of rapamycin, C51H79NO13. Can. J. Chem. 56, 2491-2492. doi: 10.1139/v78-407
120. Swinney, D. C., and Anthony, J. (2011). How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519. doi: 10.1038/nrd3480
121. Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez Lazaro, L., et al. (2001). Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19, 1256-1265.
122. Taft, F., Brünjes, M., Floss, H. G., Czempinski, N., Grond, S., Sasse, F., et al. (2008). Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. Chembiochem 9, 1057-1060. doi: 10.1002/cbic.200700742
123. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. (1999). Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. U.S.A. 96, 7196-7201. doi: 10.1073/pnas.96.13.7196
124. Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., et al. (2001). Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961-966. doi: 10.1038/91008
125. Tang, R., Faussat, A.-M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., et al. (2006). Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol. Cancer Ther. 5, 723-731. doi: 10.1158/1535-7163.mct-05-0164
126. Thaler, F., and Mercurio, C. (2014). Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. ChemMedChem 9, 523-536. doi: 10.1002/cmdc.201300413
127. Thuaud, F., Ribeiro, N., Nebigil, C. G., and Désaubry, L. (2013). Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chem. Biol. 20, 316-331. doi: 10.1016/j.chembiol.2013.02.006
128. Ueda, H., Nakajima, H., Hori, Y., Goto, T., and Okuhara, M. (1994). Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58, 1579-1583.
129. Uemura, D., Takahashi, K., Yamamoto, T., Katayama, C., Tanaka, J., Okumura, Y., et al. (1985). Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J. Am. Chem. Soc. 107, 4796-4798. doi: 10.1021/ja00302a042
130. Vandermolen, K. M., McCulloch, W., Pearce, C. J., and Oberlies, N. H. (2011). Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. (Tokyo) 64, 525-531. doi: 10.1038/ja.2011.35
131. Vasaitis, T. S., and Njar, V. C. O. (2010). Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Med. Chem. 2, 667-680. doi: 10.4155/fmc.10.14
132. Vezina, C., Kudelski, A., and Sehgal, S. N. (1975). Rapamycin (AY 22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726.
133. Villalona-Calero, M. A., Eckhardt, S. G., Weiss, G., Hidalgo, M., Beijnen, J. H., Van Kesteren, C., et al. (2002). A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin. Cancer Res. 8, 75-85.
134. Vlahov, I. R., and Leamon, C. P. (2012). Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug. Chem. 23, 1357-1369. doi: 10.1021/bc2005522
135. Von Hoff, D. D. (1998). There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079-1086.
136. Vrignaud, P., Sémiond, D., Lejeune, P., Bouchard, H., Calvet, L., Combeau, C., et al. (2013). Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 19, 2973-2983. doi: 10.1158/1078-0432.ccr-12-3146
137. Wang, A. Z., Langer, R., and Farokhzad, O. C. (2012). Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198. doi: 10.1146/annurev-med-040210-162544
138. Watson, C. J. E., Friend, P. J., Jamieson, N. V., Frick, T. W., Alexander, G., Gimson, A. E., et al. (1999). Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67, 505-509. doi: 10.1097/00007890-199902270-00002
139. Weedon, D., and Chick, J. (1976). Home treatment of basal cell carcinoma. Med. J. Aust. 1, 928.
140. Xu, Z. (2011). Modernization: one step at a time. Nature 480, S90-S92. doi: 10.1038/480S90a
141. Yadav, V. G., De Mey, M., Giaw Lim, C., Kumaran Ajikumar, P., and Stephanopoulos, G. (2012). The future of metabolic engineering and synthetic biology: towards a systematic practice. Metab. Eng. 14, 233-241. doi: 10.1016/j.ymben.2012.02.001
142. Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X., and Low, P. S. (2006). Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl. Acad. Sci. U.S.A. 103, 13872-13877. doi: 10.1073/pnas.0601455103
143. Yang, Z., He, Y., Vourloumis, D., Vallberg, H., and Nicolaou, K. C. (1997). Total synthesis of epothilone A: the olefin metathesis approach. Angew. Chem. Int. Ed. Engl. 36, 166-168. doi: 10.1002/anie.199701661
144. Zard, S. Z. (2012). Some aspects of the chemistry of nitro compounds. Helv. Chim. Acta 95, 1730-1757. doi: 10.1002/hlca.201200324
145. Zewail-Foote, M., and Hurley, L. H. (1999). Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42, 2493-2497. doi: 10.1021/jm990241l
146. Zewail-Foote, M., Li, V.-S., Kohn, H., Bearss, D., Guzman, M., and Hurley, L. H. (2001). The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8, 1033-1049. doi: 10.1016/S1074-5521(01)00071-0
147. Zheng, S., Chan, C., Furuuchi, T., Wright, B. J. D., Zhou, B., Guo, J., et al. (2006). Stereospecific formal total synthesis of ecteinascidin 743. Angew. Chem. Int. Ed. Engl. 45, 1754-1759. doi: 10.1002/anie.200503983